ArticlePloS one2017
Evolution of EBV seroprevalence and primary infection age in a French hospital and a city laboratory network, 2000-2016.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 76 citations in OpenAlex.
- Sex- and age-specific incidence and fraction of hospital contacts for infectious mononucleosis cases in Denmark in 1977-2011.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Analysis of clinical characteristics and risk factors for severe EBV infection in children-a single-center retrospective cohort study.BMC pediatrics · 2026Article
- IgA nephropathy: a novel pathway in immunopathogenesis dependent on the timing of Epstein-Barr virus infection.Frontiers in immunology · 2026Review
- Article
- Retrospective In Silico Analysis of Routine Laboratory Data Supports a Specific Association of Epstein-Barr Virus and Multiple Sclerosis.European journal of neurology · 2025Article
- Population-Based Incidence of Infectious Mononucleosis and Related Hospitalizations: 2010 Through 2021.Mayo Clinic proceedings · 2025Article
- Clinical Features and Laboratory Findings of Hospitalized Children with Infectious Mononucleosis Caused by Epstein-Barr Virus from Croatia.Pathogens (Basel, Switzerland) · 2025Article
- Evolution of Epstein-Barr Virus Infection Seroprevalence in a French University Hospital over 11 Years, Including the COVID-19 Pandemic, 2013-2023.Microorganisms · 2025Article
- Clinical significance and pathogenesis of GBP5 in infectious mononucleosis associated liver injury.Italian journal of pediatrics · 2025Article
- Article
- Immunoregulatory therapy restores T cell subset balance and reveals risk factors for liver injury in children with infectious mononucleosis.American journal of translational research · 2025Article
- Global, regional, and national burden of pediatric nasopharyngeal carcinoma (1990-2021) and projections of future disease burden trends.Frontiers in pediatrics · 2025Article
- Quantitative assessment of multiple pathogen exposure and immune dynamics at scale.Microbiology spectrum · 2024Article
- Review
- Seroprevalence of Epstein-Barr virus infection in children during the COVID-19 pandemic in Zhejiang, China.Frontiers in pediatrics · 2023Article
- Prevention of OncogenicTransplant international : official journal of the European Society for Organ Transplantation · 2023Review
- Temporal Trends in the Incidence of Hemophagocytic Lymphohistiocytosis: A Nationwide Cohort Study From England 2003-2018.HemaSphere · 2022Article
- Epidemiological characteristics and disease burden of infectious mononucleosis in hospitalized children in China: A nationwide retrospective study.Virologica Sinica · 2022Article
- Declining Epstein-Barr Virus Antibody Prevalence in College Freshmen Strengthens the Rationale for a Prophylactic EBV Vaccine.Vaccines · 2022Article
- Epstein-Barr virus and Burkitt's lymphoma. Associations in Iraqi Kurdistan and twenty-two countries assessed in the International Incidence of Childhood Cancer.Infectious agents and cancer · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccording to rare studies, the age at EBV primary infection (PI) has recently risen in some developed countries. A later age at infection is generally considered a risk factor for severe EBV PI, although few studies exist on this subject. Our investigation aimed to determine whether EBV seroprevalence and EBV PI epidemiology have evolved in France, and to what extent age and infection intensity (regarding biological parameters) are correlated. METHODS AND
findingsWe conducted a retrospective study of the following EBV serological tests databases: tests carried out at Grenoble University Hospital (2000-2016) (n = 53,553); and tests carried out by a network of city laboratories in Grenoble area (2008-2015) (n = 27,485). The hospital population showed a continuous, significant decrease in EBV seroprevalence over the studied period for patients aged 20 and over (p<0.01). The seroprevalence also decreased for different age classes (<10, 15-19, 20-30, and 30-40 years old) over the periods 2001-2005, 2006-2010, and 2011-2015. Consistently, the age at PI was significantly higher in the years 2008-2015 than in the years 2001-2007 (15.6±12.0 vs. 13.7±11.0; p = 0.03). The city laboratory population showed the same trend of decreasing seroprevalence (p = 0.06); no significant variations in age at PI were observed. The age at PI was positively correlated with ASAT, ALAT, γGT, and bilirubin blood levels (p<0.01) and negatively correlated with platelet counts (p<0.05).
conclusionIn the last 15 years, the age at EBV PI has increased, whereas seroprevalence has decreased. Moreover, our findings confirm the positive correlation between age and biological abnormalities. Taken together, these results suggest that the incidence of severe EBV PI will increase in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.